This drop is no different than any other pressure drop prior to a successful buyout by a large pharma. Think about it, between Adam F and the early/current lawsuit its not hard to figure out. Its also very likely the low institutional ownership is in large part due to no secondaries being offered thus the fear uncertainty and doubt sowed by the above characters and many here.